Business
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and
About this update from Sensei Biotherapeutics, Inc.
[{"type":"text","content":"BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that the company will present preclinical data on its conditionally active immuno-oncology programs at upcoming scientific conferences. Details of the company’s presentations are as follows: Keystone Symposia’s Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming ResistanceTitle: VISTA checkpoint targeting by SNS-101, a pH-selective antibody with enhanced safety and pharmacokinetic profiles, alters the tumor microenvironment and overcomes immune checkpoint inhibitor resistance Presenter: Edward van der Horst, Ph.D., Chief Scientific Officer Session: Progress in Drugging the TIGIT and VISTA Pathways Date and time: Tuesday, March 19, 2024, 3 – 4:30 p.m. PT Material from the presentation will also be presented in a poster at the conference, as detailed: Poster Number: 3021 Session: Poster Session 3 Date and time: Wednesday, March 20, 2024, at 7:30 p.m. PTAmerican Association for Cancer Research (AACR) Annual Meeting 2024Title: Conditionally active CD28xVISTA bispecific antibodies induce myeloid-driven tumor-specific T-cell co-stimulation for improved cancer immunotherapyPresentation Type: Poster PresentationSession Category: ImmunologySession Title: Immune Modulation Employing Agonist or Co-Stimulatory ApproachesDate and Time: Tuesday, April 9, 2024, 1:30 p.m. - 5:00 p.m. PTLocation: Poster Section 3 Abstract Number: 5294 About Sensei Biotherapeutics Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is als...